镭-223治疗转移性去势抵抗性前列腺癌的总生存期种族差异
该研究回顾性分析了美国退伍军人事务部系统中318例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,其中黑人87例(27%)。黑人患者起始镭-223时更年轻、PSA和碱性磷酸酶更高、既往多西他赛暴露比例更高,但多因素分析显示黑人种族与镭-223起始后死亡风险降低相关(HR 0.75,95%CI 0.57-0.99,p=0.045)。
要点
- 黑人患者接受镭-223时更年轻且疾病负荷更重(PSA、ALP更高)。
- 黑人种族与镭-223起始后死亡风险降低独立相关(HR 0.75)。
- 需进一步研究验证并探索黑白种族间的生物学差异。
核心结论
- 黑人转移性去势抵抗性前列腺癌患者接受镭-223后总生存期长于非黑人患者,尽管其似乎更晚接受镭-223治疗。
研究设计与样本
- 回顾性队列研究,审查美国退伍军人事务部系统中所有接受镭-223治疗的318例患者,其中黑人87例(27%)。
主要发现
- 黑人患者起始镭-223时中位年龄67岁 vs 非黑人70岁(p<0.001)。
- 黑人患者中位PSA 159.9 vs 90.2 ng/ml(p=0.014),中位碱性磷酸酶163 vs 135 IU/l(p=0.017)。
- 黑人患者既往多西他赛暴露比例77% vs 55%(p<0.001)。
- 多因素分析显示黑人种族与镭-223起始后死亡风险降低相关(HR 0.75,95%CI 0.57-0.99,p=0.045)。
临床怎么用
- 真实世界中黑人患者接受镭-223时疾病特征更重,但生存获益可能更优,提示需关注治疗时机与种族差异。
局限性
- 回顾性研究设计,样本仅来自退伍军人事务部系统,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several recent studies on metastatic castration resistant prostate cancer demonstrated improved overall survival in black vs white men. 223Radium is Food and Drug Administration approved for metastatic castration resistant prostate cancer based on a survival benefit in the ALSYMPCA (A Phase III Study of Radium-223 Dichloride in Patients with Symptomatic Hormone Refractory Prostate Cancer with Skeletal Metastases) trial, in which 94% of participants were white. We identified a real world population of patients with metastatic castration resistant prostate cancer who received 223radium to compare differences in baseline characteristics and outcomes in black vs nonblack men. MATERIALS AND METHODS: We reviewed the charts of all men who received 223radium in the entire Veterans Affairs system. We compared treatment patterns and baseline characteristics between black and nonblack men. We used Cox models to analyze predictors of time from 223radium start to overall survival and time to skeletal related events. RESULTS: We identified 318 patients treated with 223radium, including 87 (27%) who were black. Median followup after 223radium initiation was 25.3 months (IQR 13.8-37.1). Black men were younger than nonblack men when starting 223radium (median age 67 vs 70 years, p <0.001) and they had higher prostate specific antigen (median 159.9 vs 90.2 ng/ml, p=0.014) and alkaline phosphatase (median 163 vs 135 IU/l, p=0.017). A greater proportion of black men received docetaxel prior to 223radium (77% vs 55%, p <0.001). On multivariable analysis black race was associated with a decreased risk of mortality from the time of 223radium initiation (HR 0.75, 95% CI 0.57-0.99, p=0.045). CONCLUSIONS: Black men had longer overall survival than nonblack men, although they appeared to receive radium later in the disease course. Further studies are required to verify our findings and explore biological differences between black and nonblack men with metastatic castration resistant prostate cancer.
引用
- Zhao H, Howard LE, De Hoedt A, et al. Racial Discrepancies in Overall Survival among Men Treated with 223Radium. J Urol. 2019. PMID: 31479407. doi:10.1097/JU.0000000000000524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。